| Literature DB >> 33094916 |
Luana Martins de Carvalho1,2,3, Pablo A S Fonseca4,5, Isadora M Paiva1, Samara Damasceno1, Agatha S B Pedersen1, Daniel da Silva E Silva6, Corinde E Wiers2, Nora D Volkow2,7, Ana L Brunialti Godard1.
Abstract
Gene prioritization approaches are useful tools to explore and select candidate genes in transcriptome studies. Knowing the importance of processes such as neuronal activity, intracellular signal transduction, and synapse plasticity to the development and maintenance of compulsive ethanol drinking, the aim of the present study was to explore and identify functional candidate genes associated with these processes in an animal model of inflexible pattern of ethanol intake. To do this, we applied a guilt-by-association approach, using the GUILDify and ToppGene software, in our previously published microarray data from the prefrontal cortex (PFC) and striatum of inflexible drinker mice. We then tested some of the prioritized genes that showed a tissue-specific pattern in postmortem brain tissue (PFC and nucleus accumbens (NAc)) from humans with alcohol use disorder (AUD). In the mouse brain, we prioritized 44 genes in PFC and 26 in striatum, which showed opposite regulation patterns in PFC and striatum. The most prioritized of them (i.e., Plcb1 and Prkcb in PFC, and Dnm2 and Lrrk2 in striatum) were associated with synaptic neuroplasticity, a neuroadaptation associated with excessive ethanol drinking. The identification of transcription factors among the prioritized genes suggests a crucial role for Irf4 in the pattern of regulation observed between PFC and striatum. Lastly, the differential transcription of IRF4 and LRRK2 in PFC and nucleus accumbens in postmortem brains from AUD compared to control highlights their involvement in compulsive ethanol drinking in humans and mice.Entities:
Keywords: GUILDify; IRF4; LRRK; ToppGene OR guilt-by-association approaches; alcohol use disorders; microarray data; prefrontal cortex; striatum
Mesh:
Substances:
Year: 2020 PMID: 33094916 PMCID: PMC7749619 DOI: 10.1002/brb3.1879
Source DB: PubMed Journal: Brain Behav Impact factor: 3.405
Figure 1Workflow of gene prioritization on the microarrays analysis in Prefrontal cortex (PFC) and striatum of inflexible drinker mice. Using keywords that describe the biological process that underlies addiction and compulsive ethanol intake, GUILDify generated a list of genes associated with these phenotypes (trained list). ToppGene related the functional information of the trained list genes with candidate genes of the microarray of each structure separately through a fuzzy‐based multivariate analysis, which generated a list of prioritized genes. WebGestalt was used to perform Gene Ontology and metabolic pathway enrichment analyses for the prioritized genes in PFC and striatum with assistance of an overrepresentation enrichment analysis. Subsequently, the most functional relevant enriched terms were selected and the Hamming distance among the genes was estimated using an incidence matrix composed of the genes and the terms. Subsequently, the Hamming distance was used to calculate the Euclidian distance and the prioritized genes were clustered. Finally, NetworkAnalyst was used to identify potential transcription factors with higher regulatory potential for the prioritized genes in PFC and striatum. The microarray data are available on the Gene Expression Omnibus (GEO), NCBI, and can be assessed using the following ID: GSE123114
Prioritized genes in prefrontal cortex. ToppGene related the functional information (retrieved from Gene Ontology; PubMed publications; coexpression pattern; and diseases) of the trained list genes with candidate genes of the microarray of each structure separately through a fuzzy‐based multivariate analyze, which generated a list of prioritized genes. *Genes were prioritized in both prefrontal cortex and striatum. The microarray data are available on the Gene Expression Omnibus (GEO), NCBI, and can be assessed using the following ID: GSE123114
| Prefrontal Cortex | |||
|---|---|---|---|
| Gene Symbol | Gene ID | Description |
|
|
| 301 | Annexin A1 | 1,44E−04 |
|
| 324 | APC regulator of WNT signaling pathway | 5,21E−05 |
|
| 478 | Atpase Na+/K + transporting subunit alpha 3 | 5,67E−05 |
|
| 567 | Beta−2 microglobulin | 1,18E−04 |
|
| 8,913 | Calcium voltage‐gated channel subunit alpha1 G | 1,68E−04 |
|
| 815 | Calcium/calmodulin‐dependent protein kinase II alpha | 7,83E−05 |
|
| 816 | Calcium/calmodulin‐dependent protein kinase II, beta | 1,28E−04 |
|
| 8,573 | Calcium/calmodulin‐dependent serine protein kinase | 1,74E−04 |
|
| 999 | Cadherin 1 | 6,79E−05 |
|
| 1,026 | Cyclin‐dependent kinase inhibitor 1A | 1,72E−04 |
|
| 6,387 | Chemokine ligand 12 | 4,12E−05 |
|
| 1644 | Dopa decarboxylase | 2,29E−04 |
|
| 1759 | Dynamin 1 | 6,97E−05 |
|
| 1813 | Dopamine receptor D2 | 1,16E−04 |
|
| 2065 | Erb‐b2 receptor tyrosine kinase 3 | 4,43E−05 |
|
| 2,335 | Fibronectin 1 | 5,25E−05 |
|
| 2,353 | FBJ osteosarcoma oncogene | 8,11E−05 |
|
| 2,555 | GABA A receptor, subunit alpha 2 | 1,85E−04 |
|
| 2,562 | GABA A receptor, subunit beta 3 | 4,30E−05 |
|
| 2,771 | G‐protein subunit alpha i2 | 1,47E−04 |
|
| 2,890 | Glutamate ionotropic receptor AMPA type subunit 1 | 9,54E−05 |
|
| 3,119 | Major histocompatibility complex, class II, DQ beta 1 | 3,15E−05 |
|
| 3,479 | Insulin‐like growth factor 1 | 6,79E−05 |
|
| 3,725 | Jun proto‐oncogene | 1,23E−04 |
|
| 3,785 | Potassium voltage‐gated channel subfamily Q member 2 | 8,24E−05 |
|
| 3,815 | KIT proto‐oncogene receptor tyrosine kinase | 2,45E−05 |
|
| 3,984 | LIM domain‐containing, protein kinase | 1,40E−04 |
|
| 4,035 | Low‐density lipoprotein receptor‐related protein 1 | 2,19E−04 |
|
| 4,137 | Microtubule‐associated protein tau | 5,15E−07 |
|
| 4,208 | Myocyte enhancer factor 2C | 8,03E−05 |
|
| 8,829 | Neuropilin 1 | 2,19E−04 |
|
| 5,155 | Platelet derived growth factor, B polypeptide | 3,17E−05 |
|
| 23,236 | Phospholipase C, beta 1 | 7,44E−05 |
|
| 5,332 | Phospholipase C, beta 4 | 1,24E−04 |
|
| 5,575 | Protein kinase, camp‐dependent regulatory, type I beta | 2,15E−04 |
|
| 5,580 | Protein kinase C, delta | 9,55E−05 |
|
| 6,505 | Solute carrier family, member 1 | 2,19E−04 |
|
| 6,772 | Signal transducer and activator of transcription 1 | 1,88E−04 |
|
| 6,804 | Syntaxin 1A | 7,43E−05 |
|
| 7,042 | Transforming growth factor, beta 2 | 6,95E−05 |
|
| 7,043 | Transforming growth factor, beta 3 | 1,73E−04 |
|
| 7,054 | Tyrosine hydroxylase | 7,06E−05 |
|
| 7,474 | Wnt family member 5A | 1,55E−04 |
|
| 7,534 | Tyrosine 3‐monooxygenase/tryptophan 5‐monooxygenase activation protein zeta | 1,29E−04 |
Prioritized genes in striatum. ToppGene related the functional information (retrieved from Gene Ontology; PubMed publications; coexpression pattern; and diseases) of the trained list genes with candidate genes of the microarray of each structure separately through a fuzzy‐based multivariate analysis, which generated a list of prioritized genes. *Genes were prioritized in both prefrontal cortex and striatum. The microarray data are available on the Gene Expression Omnibus (GEO), NCBI, and can be assessed using the following ID: GSE123114
| Striatum | |||
|---|---|---|---|
| Gene Symbol | Gene ID | Description | p‐value |
|
| 478 | Atpase Na+/K + transporting subunit alpha 3 | 1,83E−05 |
|
| 6,311 | Ataxin 2 | 4,33E−05 |
|
| 659 | Bone morphogenetic protein receptor, type II | 1,88E−04 |
|
| 673 | Braf transforming gene | 4,08E−05 |
|
| 781 | Calcium channel, voltage‐dependent, alpha2/delta subunit 1 | 1,88E−04 |
|
| 815 | Calcium/calmodulin‐dependent protein kinase II alpha | 3,83E−05 |
|
| 1,027 | Cyclin‐dependent kinase inhibitor 1B | 1,06E−04 |
|
| 1759 | Dynamin 1 | 3,08E−05 |
|
| 1785 | Dynamin 2 | 6,12E−05 |
|
| 1813 | Dopamine receptor D2 | 4,73E−05 |
|
| 2,562 | GABA A receptor, subunit beta 3 | 1,34E−05 |
|
| 2,890 | Glutamate receptor, ionotropic, AMPA1 (alpha 1) | 2,80E−05 |
|
| 1839 | Heparin‐binding EGF‐like growth factor | 1,86E−04 |
|
| 3,312 | Heat shock protein 8 | 1,99E−04 |
|
| 3,662 | Interferon regulatory factor 4 | 7,62E−05 |
|
| 8,997 | Kalirin, rhogef kinase | 2,20E−04 |
|
| 3,763 | Potassium inwardly rectifying channel subfamily J member 6 | 1,00E−04 |
|
| 23,095 | Kinesin family member 1B | 2,12E−04 |
|
| 5,599 | Mitogen‐activated protein kinase 8 | 2,13E−04 |
|
| 4,208 | Myocyte enhancer factor 2C | 1,39E−04 |
|
| 5,048 | Platelet‐activating factor acetylhydrolase, isoform 1b, subunit 1 | 1,11E−04 |
|
| 5,577 | Protein kinase, camp‐dependent regulatory, type II beta | 1,08E−04 |
|
| 6,323 | Sodium channel, voltage‐gated, type I, alpha | 7,14E−05 |
|
| 6,324 | Sodium channel, voltage‐gated, type I, beta | 8,34E−05 |
|
| 6,506 | Solute carrier family 1, member 2 | 1,18E−04 |
|
| 6,853 | Synapsin I | 1,94E−04 |
Figure 2Circle plots for the most functionally relevant enriched terms for PFC (first row) and striatum (second row), depicting the relationship between the enriched terms and the gene expression profile for biological processes (first column) and KEGG pathways (second column). The outer circle indicates the up‐ (red dots) or downregulate (blue dots) state of each gene associated with each term. The inner circle represents the z‐score calculated for each term using the number of up‐ and downregulated genes. Negative z‐scores indicate a downregulation of the genes annotated for the current biological process or KEGG pathways. Positive z‐scores indicate upregulation of the genes annotated for the current biological process or KEGG pathways. For the biological process enriched terms in PFC and striatum, only the 10 most significant terms were shown in order to keep all the IDs legible
Figure 3TF‐target gene network for the prioritized genes identified in the PFC (a) and striatum (b). The blue squares represent the potential transcription factors (TFs), and the circles, the prioritized genes. Each edge between a TF and a gene represents a potential regulatory activity. The colors of the circles, as well as the area of the circle, represent the number of possible TFs associated with this gene. The darker the red colors of the circle, the larger the number of TFs associated with it
Top 10 transcription factors (TFs) with the highest centrality metrics in prefrontal cortex (PFC) and striatum
| To 10 TF for centrality metric | |||
|---|---|---|---|
| Prefrontal Cortex | Striatum | ||
| Gene symbol | Degree/ Betweenness | Gene symbol | Degree/ Betweenness |
|
| 14/272.37 |
| 6/93.25 |
|
| 9/199.78 |
| 5/127.11 |
|
| 8/75.07 |
| 4/91.13 |
|
| 8/72.63 |
| 4/25.43 |
|
| 7/60.71 |
| 4/20.57 |
|
| 7/52.27 |
| 3/43.51 |
|
| 5/43.89 |
| 3/26.47 |
|
| 5/33.49 |
| 3/26.47 |
|
| 5/33.49 |
| 3/26.47 |
|
| 5/33.15 |
| 3/25.39 |
Figure 4Venn diagram representing the sharing pattern among the prioritized genes. PFC (red ellipse), striatum (blue ellipse), and the potential transcription factors (TFs) in PFC (purple ellipse) and striatum (green ellipse)
Figure 5Multidimensional scaling plot (MDS) clustering the prioritized genes identified in the PFC (red symbols), striatum (green symbols), and both tissues (blue symbols) based on the functional annotation. The genes were clustered based on the Euclidian distance obtained from the hamming distance for the incidence matrix composed by genes and the most functionally relevant enriched GO and KEGG terms. The red circle highlights the position of the IRF4 gene
Demographic and clinical characteristics of alcohol use disorder (AUD) and control subjects. BMI = body mass index; PMI = postmortem interval (hour); BAC = blood alcohol concentration (g/100ml) at death
| Characteristics | AUD ( | Controls ( |
|
|---|---|---|---|
| Age | 50.55 ± 6.07 | 49.94 ± 11.32 |
|
| BMI | 24.64 ± 5.40 | 33 ± 1.46 |
|
| PMI | 38.91 ± 12.69 | 31.06 ± 13.94 |
|
| Brain Weight | 1,387.73 ± 127.71 | 1506.63 ± 106.81 |
|
| Age onset drinking | 18.55 ± 4.13 | 24 ± 4.86 |
|
| BAC | 0.197 ± 0.14 | 0.002 ± 0.008 |
|
| Drinking (g/day) | 233.27 ± 118.09 | 18.51 ± 19.87 |
|
| Drinks per week | 125.36 ± 89.99 | 9.81 ± 9.60 |
|
| Pack‐years cigarettes | 45.09 ± 19.22 | 4.07 ± 13.87 |
|
Figure 6Relative mRNA quantification in postmortem brain tissue from alcohol use disorder (AUD) and control subjects. Prefrontal cortex (PFC) and nucleus accumbens (NAc). Relative mRNA levels of (a) IRF4, (b) PLCB1, (c) PRKCB, (d) IRF4, (e) LRRK2, and (f) DNM2. In a, d, and e, *# p < .05 different from control. IFR4 in NAC (p = .034, q = 0.066) and PFC (p = .030, q = 0.066) and LRRK2 (p = .005, q = 0.030) in NAc, survived the FDR 5% correction. Unpaired t test was used to analyze the differences between the groups for IRF4 and DNM2 in NAc and for IRF4 and PRKCB in PFC. Mann–Whitney was used to analyze LRRK2 in NAc and PLCB1 in PFC. Results are presented as mean ± SEM for (a, c, d, and f) and median with 95% CI for (b and e)